On August 6th, Dynamite is releasing a new series written by Peter Milligan (X-STATIX, HELLBLAZER). The series deals a man with a terminal disease who is given a mysterious treatment to save his life. Milligan answered a few of our questions about the upcoming Dynamite series.
Clik here to view.

COMIC VINE: What can readers expect from TERMINAL HERO?
PETER MILLIGAN: Terminal Hero is a dark, edgy and sometimes surreal thriller about a man who'll do anything to stay alive.
CV: Where did the idea for Terminal Hero come from?
PM: A friend developed a brain tumor, seeing him and seeing him deal with the side-effects of his treatment, got me thinking about the nature of life and death, and how our perceptions of who we are might be torn apart.
CV: What's different about Rory Fletcher compared to other characters you've written?
PM: He's nicer than my usual characters. When we meet him he's a really good guy. He wants to help people. He's just the kind of person who doesn't deserve to get a terminal brain tumor.
CV: Fletcher is cured with Treatment Q, but it comes at a cost, what are some of the side effects of this treatment?
PM: The most harrowing episodes concern his sister, who died when Rory was a kid. This pure relationship is turned into something lewd and horrible. Are these side effects? Or is Rory simply seeing himself for what he really is?
CV: What does Piotr Kowalski add to this book?
PM: Piotr's great with character and emotion, and they're such important elements of the book.
CV: What do you enjoy most about this book, so far?
PM: There is a kind of guilty sick pleasure if watching this decent guy go through a kind of modern, comic book, weird version of the Book of Job.
CV: Anything else you'd like to tell us about the series?
PM: Terminal Hero is a dark, nightmarish, and sometimes brutally sexual. It's really not afraid to go to some very harrowing places.
Make sure to check out TERMINAL HERO on August 6th and take a look at some of these interiors!
Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.
